These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 18455581)

  • 21. Clinical significance of p53 in non-small-cell lung cancer.
    Komiya T; Hirashima T; Kawase I
    Oncol Rep; 1999; 6(1):19-28. PubMed ID: 9864395
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Absence of prognostic significance of p21(WAF1/CIP1) protein expression in non-small cell lung cancer.
    Dworakowska D; Jassem E; Jassem J; Boltze C; Wiedorn KH; Dworakowski R; Skokowski J; Jaśkiewicz K; Czestochowska E
    Acta Oncol; 2005; 44(1):75-9. PubMed ID: 15848909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Postoperative complications after induction chemoradiotherapy in patients with non-small-cell lung cancer.
    Fujita S; Katakami N; Takahashi Y; Hirokawa K; Ikeda A; Tabata C; Mio T; Mishima M
    Eur J Cardiothorac Surg; 2006 Jun; 29(6):896-901. PubMed ID: 16675259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications.
    Horowitz J
    Curr Opin Mol Ther; 1999 Aug; 1(4):500-9. PubMed ID: 11713766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential increase in the prognostic value of p53 mutation by Pro72 allele in stage I non-small-cell lung cancer.
    Chien WP; Wong RH; Wu TC; Cheng YW; Chen CY; Lee H
    Ann Surg Oncol; 2009 Jul; 16(7):1918-24. PubMed ID: 19434453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment.
    Zalcman G; Schlichtholz B; Trédaniel J; Urban T; Lubin R; Dubois I; Milleron B; Hirsch A; Soussi T
    Clin Cancer Res; 1998 Jun; 4(6):1359-66. PubMed ID: 9626451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pneumonectomy after chemotherapy: morbidity, mortality, and long-term outcome.
    Alifano M; Boudaya MS; Salvi M; Collet JY; Dinu C; Camilleri-Broët S; Régnard JF
    Ann Thorac Surg; 2008 Jun; 85(6):1866-72; discussion 1872-3. PubMed ID: 18498785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene.
    Fujiwara T; Grimm EA; Mukhopadhyay T; Zhang WW; Owen-Schaub LB; Roth JA
    Cancer Res; 1994 May; 54(9):2287-91. PubMed ID: 8162565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
    Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A case of advanced non-small lung cancer responding to tumor suppressor p53 gene therapy].
    Kagawa S; Ohtani S; Tanaka N; Fujiwara T
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1788-90. PubMed ID: 15553716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant chemotherapy and pneumonectomy in a lung cancer patient on hemodialysis.
    Melloni G; Casiraghi M; Ciriaco P; Puglisi A; Libretti L; Bandiera A; Sayed I; Zannini P
    Thorac Cardiovasc Surg; 2005 Dec; 53(6):382-3. PubMed ID: 16311978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma.
    Ott K; Vogelsang H; Mueller J; Becker K; Müller M; Fink U; Siewert JR; Höfler H; Keller G
    Clin Cancer Res; 2003 Jun; 9(6):2307-15. PubMed ID: 12796400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. P53-independent thermosensitization by mitomycin C in human non-small-cell lung cancer cells.
    Jin ZH; Matsumoto H; Hayashi S; Hatashita M; Ohtsubo T; Shioura H; Kitai R; Kano E
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):852-60. PubMed ID: 15183489
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dosimetric analysis of the patterns of local failure observed in patients with locally advanced non-small cell lung cancer treated with neoadjuvant chemotherapy and concurrent conformal (3D-CRT) chemoradiation.
    Moreno-Jiménez M; Aristu J; López-Picazo JM; Ramos LI; Gúrpide A; Gómez-Iturriaga A; Valero J; Martínez-Monge R
    Radiother Oncol; 2008 Sep; 88(3):342-50. PubMed ID: 18558448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer.
    Früh M; Rolland E; Pignon JP; Seymour L; Ding K; Tribodet H; Winton T; Le Chevalier T; Scagliotti GV; Douillard JY; Spiro S; Shepherd FA
    J Clin Oncol; 2008 Jul; 26(21):3573-81. PubMed ID: 18640938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A; Sørensen JB
    Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical study of adenoviral mediated p53 gene therapy for non-small cell lung cancer in Japan].
    Kagawa S; Fujiwara T; Tanaka N
    Gan To Kagaku Ryoho; 2003 Feb; 30(2):193-7. PubMed ID: 12610865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer.
    Pan JH; Han JX; Wu JM; Sheng LJ; Huang HN; Yu QZ
    Respiration; 2008; 75(4):380-5. PubMed ID: 17851225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction therapy of loco-regional non-small-cell lung cancer with reliable response and low toxicity (low dose radiotherapy sensitizes tumor to subsequent chemotherapy?).
    Takita H; Shin KH; Soh AY; Yi WS; Wilding G
    Lung Cancer; 2009 Mar; 63(3):387-92. PubMed ID: 18676056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [p53 mutation and chemoresistance in oral-maxillofacial squamous cell carcinoma. Role of p53 in the cell cycle control and in the modulating action of chemotherapeutic agents].
    Cutilli T; Papola F; Di Emidio P; Corbacelli A
    Minerva Stomatol; 1997 Dec; 46(12):671-8. PubMed ID: 9567617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.